Matthew Rabinowitz Net Worth

Matthew Rabinowitz has an estimated net worth of $2.1 billion, according to Forbes Real-Time Billionaires, Matthew Rabinowitz profile (figures as of October 20, 2026).

Matthew Rabinowitz is an entrepreneur and investor best known as the cofounder and executive chairman of Natera, a clinical genetic testing and molecular diagnostics company. His work has focused on diagnostics, biotech, machine learning, health services, and conservation. Earlier in his career, he cofounded Panopticon in 1998 and founded Rosum in 2000. He also served for 8 years as a consulting professor in Aeronautics and Astronautics at Stanford University.

His wealth is tied mainly to health diagnostics. In 2004, he cofounded Austin-based Natera after a family tragedy pushed him toward genetics research. The company grew into prenatal, oncology, and organ transplant testing, along with genetic counseling services. Rabinowitz and Jonathan Sheena took Natera public on the Nasdaq in 2015. He also cofounded whole genome analysis company MyOme in 2017 and owns a 19% stake there, adding another source of value.

How Matthew Rabinowitz built his wealth

Rabinowitz made his money by starting and building health technology companies. The biggest piece is Natera, where he is cofounder and executive chairman. The company works in clinical genetic testing and molecular diagnostics, with products in prenatal care, oncology, and organ transplant testing. He still owns about 2% of Natera’s shares and also holds several option tranches, so his fortune is closely tied to the company’s market value.

He also has money tied to other ventures. In 1998, he cofounded Panopticon, an online merchandising company that sold for $100 million in 2000. That same year, he founded Rosum, which developed location technology using digital TV signals to help GPS work better indoors and in dense urban areas. In 2017, he cofounded MyOme, a clinical whole genome analysis platform that became another important holding in his portfolio.

Forbes estimate and the main drivers

Forbes valued Matthew Rabinowitz at $2.1 billion on its real-time billionaires tracker as of October 20, 2026. Forbes places him in healthcare and ties his wealth to health diagnostics. It also classifies him as self-made. That estimate reflects the value of his Natera stake, his options in the company, and his ownership in MyOme, all of which come from businesses he helped create and lead.

Another factor in his finances is MyOme. Forbes notes that the company was valued at $187 million in December 2025, and Rabinowitz owns a 19% stake. Natera remains the central source of his wealth because it became a public company in 2015, giving a clear market value to the shares and options he holds. His earlier startup work shows a long record of building companies, but diagnostics is the core of his fortune.